Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707228 | 0.87 | TDP1 (0.62) | TDP1HTTKDM4EPOLBCTDSP1 | |
| SCHEMBL27860009 | 0.82 | TDP1 (0.57) | TDP1HTTKDM4EPOLBCTDSP1 | |
| SCHEMBL15774527 | 0.82 | HTT (0.46) | TDP1HTTKDM4EPOLBCTDSP1 | |
| SCHEMBL1538976 | 0.81 | TDP1 (0.56) | TDP1HTTKDM4EPOLBCTDSP1 | |
| SCHEMBL8211831 | 0.80 | TDP1 (0.59) | TDP1HTTKDM4EPOLBCTDSP1 | |
| SCHEMBL8136793 | 0.80 | ALDH1A1 (0.52) | TDP1HTTKDM4EPOLBCTDSP1 | |
| SCHEMBL14420116 | 0.80 | TDP1 (0.49) | TDP1HTTKDM4EPOLBCTDSP1 | |
| SCHEMBL2905398 | 0.79 | PKM (0.59) | TDP1HTTKDM4EPOLBCTDSP1 | |
| SCHEMBL7738286 | 0.79 | TDP1 (0.47) | TDP1HTTKDM4EPOLBCTDSP1 | |
| SCHEMBL8950203 | 0.79 | TDP1 (0.51) | TDP1HTTKDM4EPOLBCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109449-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ROCHE SEQUENCING SOLUTIONS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-20230263155-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | SPERMATECH AS (NO) | 2023-08-24 | — | — | US | disclosed |
| EP-2952587-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220064741-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2022-03-03 | — | — | US | disclosed |
| US-20180334729-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2018-11-22 | — | — | US | disclosed |
| US-9920386-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160208344-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2016-07-21 | — | — | US | disclosed |
| EP-2952587-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Stratos Genomics Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2171088-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20110251079-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110237787-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7939259-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2010084152-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| EP-2171088-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Stratos Genomics Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2009-02-05 | — | — | US | disclosed |
| WO-2008157696-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-6218388-B1 | THERAPY OF PROTEIN TYROSINE KINASE MEDIATED CANCER, ATHEROSCLEROSIS, RESTENOSIS, AND PSORIASIS BY ADMINISTERING BENZIMIDAZOLE DERIVATIVE | WARNER-LAMBERT COMPANY | 2001-04-17 | — | — | US | disclosed |
| US-5990146-A | TREATING PROTEIN TYROSINE KINASE MEDIATED CANCER; ANTICARCINOGENIC AGENTS; ATHEROSCLEROSIS; RESTENOSIS; PSORIASIS; ANTIPROLIFERATIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0056475-A2 | Pharmaceutical compositions | MERCK PATENT GmbH (DE) | 1982-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109449-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, XPNPEP1 | TDP1 140/4885HTT 1093/4885KDM4E 4042/4885 |
| US-20230263155-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | NR5A1, NR1I3, NR5A2 | TDP1 2064/4885HTT 968/4885KDM4E 3913/4885 |
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | TDP1 166/4885HTT 960/4885KDM4E 4237/4885 |
| US-20110237787-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | TDP1 166/4885HTT 960/4885KDM4E 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.